No abstract available
MeSH terms
-
Cost-Benefit Analysis
-
Drug Costs
-
Glatiramer Acetate
-
Health Services Accessibility / economics
-
Health Services Accessibility / organization & administration*
-
Humans
-
Interferons / economics
-
Interferons / supply & distribution
-
Multiple Sclerosis / drug therapy*
-
Multiple Sclerosis / economics
-
Peptides / economics
-
Peptides / supply & distribution
-
Quality-Adjusted Life Years
-
Risk Sharing, Financial
-
State Medicine / economics
Substances
-
Peptides
-
Glatiramer Acetate
-
Interferons